Minerva Neurosciences Supports Klotho's Innovative Conference on Neurodegenerative Disease Therapies

### Klotho Neurosciences Pioneers Neurodegenerative Disease Therapies at Inaugural Conference

Klotho Neurosciences, Inc. is positioned to make significant strides in the field of neurodegenerative disease treatment at the upcoming Inaugural Klotho Conference & Scientific Seminar, scheduled for September 15-16, 2025, at the UC-Irvine Beal Applied Innovation Center. This event marks a pivotal moment for the company, which specializes in Klotho-based therapeutics aimed at conditions such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and other age-related disorders. Dr. Joseph Sinkule, CEO and Chairman, will anchor Klotho's presence at the conference, which is the first of its kind focused exclusively on Klotho therapies and diagnostics.

At the conference, key scientific advisors Dr. Miguel Chillon and Dr. Assumpcio Bosch will showcase their cutting-edge research on Klotho gene therapy. Their presentations will delve into the potential of Klotho in not only treating neurodegenerative diseases but also its broader implications for enhancing longevity. This focus on longevity is especially relevant in today’s aging population, where neurodegenerative conditions are becoming increasingly prevalent. By leveraging the patented "anti-aging" human Klotho gene (s-KL), Klotho Neurosciences aims to develop innovative cell and gene therapies that could change the treatment landscape for these debilitating disorders.

The conference serves as a networking hub for Klotho, allowing Dr. Sinkule to engage directly with investors and potential partners. This interaction is crucial for fostering collaborations that could accelerate the development and commercialization of Klotho’s proprietary cell and gene therapy programs, which utilize DNA and RNA as therapeutic modalities. The management team's extensive experience in biopharmaceutical product development reinforces Klotho's position as a promising player in the biotechnology sector. However, while the company is optimistic about its future, it also acknowledges that various risks and uncertainties may impact its operational projections.

In addition to its innovative research, Klotho Neurosciences emphasizes the importance of genomic-based diagnostic assays as part of its comprehensive approach to treating neurodegenerative diseases. By integrating diagnostics with therapeutic development, Klotho seeks to create a synergistic effect that enhances patient outcomes. The upcoming conference not only highlights Klotho's commitment to advancing science but also its potential to reshape the future of treatment for age-related disorders.

As excitement builds for the Inaugural Klotho Conference, interested parties are encouraged to reach out to Klotho for potential partnerships. The event promises to be an important milestone in the ongoing quest to combat neurodegenerative diseases through innovative approaches in gene therapy and diagnostics.